BRCA Testing: Advancing Precision Breast Cancer Prevention
Understanding inherited breast cancer risk
A proportion of breast cancer cases occur due to inherited genetic changes that increase an individual’s lifetime risk of developing the disease. Among the most well-established of these are pathogenic variants in the BRCA1 and BRCA2 genes [1]
These genes play a critical role in maintaining genomic stability by supporting the repair of damaged DNA through the homologous recombination repair pathway. When BRCA1 or BRCA2 function is disrupted due to inherited variants, DNA damage may accumulate over time, increasing the likelihood of cancer development [2]
Individuals carrying pathogenic BRCA variants have a significantly elevated risk of breast cancer, as well as increased risks for other cancers, including ovarian and prostate cancer [3]
What is germline BRCA testing?
A germline BRCA test is a genetic test that analyzes a person’s inherited DNA to determine whether they carry pathogenic or likely pathogenic variants in the BRCA1 or BRCA2 genes.
Importantly, this test:
- Does not diagnose cancer
- Does not indicate the presence of cancer at the time of testing
- Is designed to assess inherited cancer predisposition and future risk
By identifying individuals with inherited risk, BRCA testing enables proactive clinical decision-making focused on prevention, early detection, and personalized risk management.
Genetic test results should always be interpreted in conjunction with a qualified healthcare professional or genetic counselor.
Why BRCA testing matters in cancer prevention
Identifying a pathogenic BRCA variant provides clinically actionable information that can guide personalized prevention strategies. Individuals found to carry such variants may benefit from tailored risk management approaches, including:
- Enhanced surveillance: More frequent and earlier cancer screening may be recommended to improve the likelihood of detecting cancer at an early, more treatable stage.
- Risk-reducing medications: In selected cases, chemoprevention strategies may be considered to help reduce the risk of cancer development.
- Risk-reducing surgery: For individuals at very high risk, preventive surgical options may significantly reduce the likelihood of developing breast or ovarian cancer.
- Personalized clinical guidance: Genetic findings can also inform broader healthcare decisions, including reproductive planning, family risk assessment, and individualized long-term monitoring strategies.
Together, these interventions support earlier action and improved outcomes through targeted risk reduction [4]
From reactive care to precision prevention
BRCA testing represents a key component of modern precision medicine, shifting the focus of oncology from treatment after disease onset to prevention and early intervention based on genetic risk.
By identifying individuals at elevated hereditary risk before cancer develops, healthcare providers can implement proactive strategies that significantly improve clinical outcomes.
This approach reflects the growing role of genomics in enabling more precise, predictive, and preventive healthcare.
DNA GTx approach to hereditary cancer testing
At DNA GTx, we provide comprehensive germline genetic testing focused on clinically relevant cancer predisposition genes, including BRCA1, BRCA2, and additional genes associated with hereditary breast, ovarian, and prostate cancer syndromes.
Our multi-gene panel approach enables broader and more detailed assessment of inherited cancer risk, supporting healthcare professionals in making informed, evidence-based clinical decisions.
By combining advanced genomic technologies with robust variant interpretation frameworks, we aim to deliver actionable insights that support:
- Early identification of individuals at increased genetic risk
- Personalized cancer prevention and surveillance strategies
- Informed clinical and family decision-making
- Improved long-term patient outcomes through precision medicine
At DNA GTx, we are committed to advancing precision oncology through high-quality genomic testing that translates complex genetic information into clinically meaningful action.
📚 References
- National Cancer Institute. BRCA Gene Changes: Cancer Risk and Genetic Testing
- Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer. 2011;12:68–78. doi:10.1038/nrc3181.
- Dubsky P, Jackisch C, Im SA, et al. BRCA genetic testing and counseling in breast cancer: how do we meet our patients’ needs? npj Breast Cancer. 2024;10:77. doi:10.1038/s41523-024-00686-8.
- Sessa C, Balmaña J, Bober SL, Cardoso MJ, Colombo N, Curigliano G, et al. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline. Ann Oncol. 2020;31(12):1857–1875. (ESMO Guidelines Committee).
Recent Blogs
有问题吗？
有具体问题或需求吗？请填写下方表格，我们的团队将尽快与您联系。
